The Impact of Multidisciplinary Discussion (MDD) in the Diagnosis and Management of Fibrotic Interstitial Lung Diseases

Table 2

Pre-MDD and MDD consensus diagnoses.

Diagnosis	Pre-MDD, n (%)	MDD, n (%)
ILD-NOS	52 (41%)	0 (0%)
HP	20 (16%)	21 (16.6%)
IPF	24 (19%)	34 (27.0%)
SR-ILD	5 (4.0%)	10 (8.0%)
NSIP	6 (4.7%)	6 (4.7%)
OP	3 (2.4%)	2 (1.6%)
Drug toxicity	4 (3.2%)	4 (3.2%)
Asbestosis	1 (0.8%)	1 (0.8%)
Sarcoidosis	4 (3.2%)	1 (0.8%)
LIP	1 (0.8%)	1 (0.8%)
GL-ILD	1 (0.8%)	1 (0.8%)
Pulmonary ossification	1 (0.8%)	1 (0.8%)
Aspiration	1 (0.8%)	1 (0.8%)
HP/IPF	2 (1.6%)	0 (0%)
DIPNECH	0 (0%)	1 (0.8%)
ILA	0 (0%)	4 (3.2%)
Cystic disease	1 (0.8%)	0 (0%)
IPAF	0 (0%)	5 (4.0%)
Unclassifiable ILD	0 (0%)	27 (21.4%)
No ILD	0 (0%)	6 (4.7%)

Includes provisional diagnoses (HP = 8, IPF = 4, and NSIP = 3). ILD = interstitial lung disease; ILD-NOS = interstitial lung disease-not otherwise specified; HP = hypersensitivity pneumonitis; IPF = idiopathic pulmonary fibrosis; SR-ILD = smoking-related ILD; NSIP = nonspecific interstitial pneumonia; OP = organising pneumonia; LIP = lymphocytic interstitial pneumonia; GL-ILD = granulomatous–lymphocytic interstitial lung disease; DIPNECH = diffuse idiopathic pulmonary neuroendocrine cell hyperplasia; ILA = interstitial lung abnormality; IPAF = interstitial pneumonia with autoimmune features.